Reviewer's report

Title: Survey of Oxaliplatin-Associated Neurotoxicity Using an Interview-Based Questionnaire in Patients with Metastatic Colorectal Cancer

Version: 1 Date: 4 July 2005

Reviewer: Timothy Maughan

Reviewer's report:

General
This is a useful article detailing the frequency, severity and quality of the neurotoxicity caused by oxaliplatin chemotherapy. It broadly conforms to previous reports but broadens the range of symptoms reported by patients which will improve the quality of the informed consent given by oncologists to their patients.

Major Compulsory Revisions (that the author must respond to before a decision on publication can be reached)

Minor Essential Revisions (such as missing labels on figures, or the wrong use of a term, which the author can be trusted to correct)

Discretionary Revisions (which the author can choose to ignore)

The term chanelaopathy (p4, para 2 line 5) I find unhelpful. Could the authors expand on this or define it in words that are more clearly understandable.

What next?: Accept after discretionary revisions

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: No

Declaration of competing interests:
I have received reimbursements and fees from Sanofi Synthelabo